293 results on '"Ghirardi, Arianna"'
Search Results
2. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
3. Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
4. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
5. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
6. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
7. Second versus first wave of COVID-19 in patients with MPN
8. Long‐term outcomes of phenoclusters in preclinical heart failure with preserved and mildly reduced ejection fraction.
9. Breakthrough infections in MPN-COVID vaccinated patients
10. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
11. Outcomes of bailout use of continuous positive airway pressure in patients with severe COVID-19 respiratory failure
12. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
13. Exploring the Clinical and Genetic Landscape of Angelman Syndrome: Patient-Reported Insights from an Italian Registry.
14. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
15. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
16. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
17. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
18. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
19. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
20. 85: PRELIMINARY RESULTS OF THE REGISTRY OF EUROPEAN CHILDREN TREATED WITH TEDUGLUTIDE
21. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
22. Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
23. Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
24. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
25. Short- and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: A population-based investigation from Italy
26. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
27. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
28. Determinants of early triage for hospitalization in myeloproliferative neoplasm ( MPN) patients with COVID ‐19
29. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
30. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
31. COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients
32. Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and 'silent hypoxemia' at admission: a severity-matched analysis
33. Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients
34. Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19
35. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study
36. Should methods of correction for multiple comparisons be applied in pharmacovigilance?
37. Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and 'silent hypoxemia' at admission: a severity-matched analysis
38. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
39. Usefulness of CURB-65, pneumonia severity index and MULBSTA in predicting COVID-19 mortality
40. Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients
41. Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: Evidence from the AIFA-BEST observational study
42. Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants
43. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria
44. The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis
45. Second Versus First Wave of COVID-19 in Patients with MPN
46. Asymptomatic hypoxia in Covid-19
47. Usefulness of CURB-65, PSI and MuLBSTA in predicting COVID-19 mortality
48. Covid-19 and gender: lower rate, but same mortality of severe disease in women
49. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study
50. Long-term follow-up of recovered MPN patients with COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.